CS-0003
GI surgical site infections (prevention)
Pre-clinical / Phase 1 anticipatedActive
Key Facts
Indication
GI surgical site infections (prevention)
Phase
Pre-clinical / Phase 1 anticipated
Status
Active
Company
About 32 Biosciences
32 Biosciences is a private, pre-revenue biotech developing first-in-class therapeutics and a discovery platform targeting the gut mucosal-immune system. Its lead asset, CS-0003, is a Mucosal Immune Modulator (MIM) aimed at preventing GI surgical site infections, with a planned Phase II trial supported by an upcoming $40M Series A round. The company's core technology measures metabolomic signatures of the gut mucosal-immune system to enable therapeutic discovery and clinical decision support across multiple GI indications.
View full company profile